COST-EFFECTIVENESS OF NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB FOR HIGH-RISK EARLYSTAGE TRIPLE-NEGATIVE BREAST CANCER (ETNBC) IN FRANCE

被引：0
|
作者：
Cagnan, L. [1 ]
Haiderali, A. [2 ]
Bensimon, L. [3 ]
Tehard, B. [4 ]
Carita, M. [5 ]
Khandelwal, A. [6 ]
Gandhi, J. [7 ]
Huang, M. [8 ]
机构：
[1] MSD France, F-76 Puteaux Paris, France
[2] Merck Co Inc, Rahway, NJ USA
[3] MSD France, F-3 Puteaux La Defense, France
[4] Vyoo Agcy, F-75 Paris, France
[5] Vyoo Agcy, Paris, France
[6] CHEORS, North Wales, PA USA
[7] Complete HEOR Solut CHEORS, North Wales, PA USA
[8] Merck Co Inc, Merck Res Labs, Rahway, NJ USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE62
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [41] Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
    Liu, Xiaoyan
    Lang, Yitian
    Liao, Yahui
    Zhu, Yizhun
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [42] OptimICE-RD: sacituzumab govitecan plus pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer
    Tolaney, Sara M.
    DeMichele, Angela
    Takano, Toshimi
    Rugo, Hope S.
    Perou, Charles
    Lynce, Filipa
    Parsons, Heather Anne
    Santa-Maria, Cesar Augusto
    Rocque, Gabrielle Betty
    Yao, Wenliang
    Sun, Shawn W.
    Mocci, Simonetta
    Partridge, Ann H.
    Carey, Lisa A.
    [J]. FUTURE ONCOLOGY, 2024,
  • [43] Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355
    Hattori, Masaya
    Masuda, Norikazu
    Takano, Toshimi
    Tsugawa, Koichiro
    Inoue, Kenichi
    Matsumoto, Koji
    Ishikawa, Takashi
    Itoh, Mitsuya
    Yasojima, Hiroyuki
    Tanabe, Yuko
    Yamamoto, Keiko
    Suzuki, Masato
    Pan, Wilbur
    Cortes, Javier
    Iwata, Hiroji
    [J]. CANCER MEDICINE, 2023, 12 (09): : 10280 - 10293
  • [44] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda
    Cescon, David
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [45] Chemokine modulation to enhance the effectiveness of pembrolizumab in patients with metastatic triple-negative breast cancer
    Abdou, Yara
    Kalinski, Pawel
    Opyrchal, Mateusz
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [46] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [47] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
    Guo, Qiusheng
    Lan, Tian
    Lu, Yunyan
    Hu, Zujian
    Xu, Haibin
    Wang, Xiaojia
    Shao, Xiying
    Fu, Xueyan
    [J]. BIOMOLECULES AND BIOMEDICINE, 2023, 23 (03): : 502 - 509
  • [49] Real-world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
    Vilbert, M. T. S.
    Corassa, M. P.
    Saleh, R. R.
    Coelho, R. L.
    Teixeira, M. R. D. J.
    Amir, E.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [50] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
    Lang, Yitian
    Chai, Qingqing
    Tao, Wenqi
    Liao, Yahui
    Liu, Xiaoyan
    Wu, Bin
    [J]. BREAST, 2023, 68 : 173 - 180
12345